NEO logo

NeoGenomics (NEO) Company Overview

Profile

Full Name:

NeoGenomics, Inc.

Sector:

Healthcare

Country:

United States

IPO:

March 16, 2004

Indexes:

Not included

Description:

NeoGenomics, Inc. is one of the leading companies in cancer diagnostics and pharmaceutical services, serving oncologists, pathologists, pharmaceutical companies, academic centers, and other specialists with innovative diagnostic and prognostic tests. The company was founded in 2002, with headquarters located in Fort Myers, Florida, USA. The clinical services segment provides cancer testing services for pathologists, oncologists, dermatologists, and other clinicians representing various communities, hospitals, and centers. The company is a leading provider of molecular sequencing and next-generation testing. The pharmaceutical services segment offers comprehensive testing services to support pharmaceutical clients' oncology programs from discovery to commercialization.

Events Calendar

Earnings

Next earnings date:

Feb 18, 2025

Recent quarterly earnings:

Nov 5, 2024

Recent annual earnings:

Feb 20, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Apr 16, 2003

Analyst ratings

Recent major analysts updates

Jan 28, 25 Goldman Sachs
Buy
Jan 16, 25 Benchmark
Hold
Jan 15, 25 Needham
Buy
Jan 13, 25 Benchmark
Hold
Jan 10, 25 Needham
Buy
Dec 13, 24 B of A Securities
Neutral
Dec 10, 24 Jefferies
Buy
Nov 6, 24 Needham
Buy
Sep 25, 24 Needham
Buy
Sep 24, 24 Benchmark
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

NEO Battery Materials Scaling-Up Production to 20 Tons Per Year for Mass-Producibility Testing
NEO Battery Materials Scaling-Up Production to 20 Tons Per Year for Mass-Producibility Testing
NEO Battery Materials Scaling-Up Production to 20 Tons Per Year for Mass-Producibility Testing
NEO
globenewswire.comFebruary 6, 2025

TORONTO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (“NEO” or the “Company”) (T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is pleased to announce the production scale-up to 20 tons per year to accommodate the increasing demand for NEO's high-performance silicon anode products and to initiate mass-producibility testing to prepare factory-level production.

NEO Battery Materials to Establish Canada's First Silicon Anode Facility on 8 Acres in Windsor, Ontario
NEO Battery Materials to Establish Canada's First Silicon Anode Facility on 8 Acres in Windsor, Ontario
NEO Battery Materials to Establish Canada's First Silicon Anode Facility on 8 Acres in Windsor, Ontario
NEO
globenewswire.comJanuary 24, 2025

TORONTO, Jan. 24, 2025 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is highly pleased to enter into a definitive lease agreement (the “Agreement”) on December 20, 2024, with the City of Windsor, Ontario (“Windsor”), securing 8 acres of surplus lands at Windsor Airport. This significant milestone marks a critical step toward establishing Canada's first advanced silicon anode manufacturing facility, further solidifying NEO's role in strengthening the Canadian battery value chain.

NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan
NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan
NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan
NEO
businesswire.comJanuary 15, 2025

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics today provided financial guidance for fiscal year 2025 and updated its Long-Range Financial Plan.

NeoGenomics (NEO) Surges 9.1%: Is This an Indication of Further Gains?
NeoGenomics (NEO) Surges 9.1%: Is This an Indication of Further Gains?
NeoGenomics (NEO) Surges 9.1%: Is This an Indication of Further Gains?
NEO
zacks.comJanuary 15, 2025

NeoGenomics (NEO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients
NEO
globenewswire.comJanuary 14, 2025

Pairing Adaptive Biotechnologies' clonoSEQ MRD results with NeoGenomics' COMPASS and CHART assessment services empowers clinicians and patients with meaningful insights across the treatment continuum Pairing Adaptive Biotechnologies' clonoSEQ MRD results with NeoGenomics' COMPASS and CHART assessment services empowers clinicians and patients with meaningful insights across the treatment continuum

NEO Battery Materials Unveils Breakthrough Silicon Battery Capacity, Expanding to Space Industry with Solid-State Batteries
NEO Battery Materials Unveils Breakthrough Silicon Battery Capacity, Expanding to Space Industry with Solid-State Batteries
NEO Battery Materials Unveils Breakthrough Silicon Battery Capacity, Expanding to Space Industry with Solid-State Batteries
NEO
globenewswire.comJanuary 7, 2025

TORONTO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is pleased to announce the launch of an advanced high-performance silicon anode product called NBMSiDE® P-300 with breakthrough battery capacity. Alongside its core focus on electric vehicles and electronics, NEO is expanding its strategic downstream focus to the space and eVTOL industries through solid-state batteries.

NeoGenomics (NEO) Upgraded to Buy: Here's Why
NeoGenomics (NEO) Upgraded to Buy: Here's Why
NeoGenomics (NEO) Upgraded to Buy: Here's Why
NEO
zacks.comDecember 30, 2024

NeoGenomics (NEO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

NEO Battery Materials and Specialty Automotive Battery Cell Manufacturer Sign Joint Development Agreement for Silicon-Enhanced Battery Technology
NEO Battery Materials and Specialty Automotive Battery Cell Manufacturer Sign Joint Development Agreement for Silicon-Enhanced Battery Technology
NEO Battery Materials and Specialty Automotive Battery Cell Manufacturer Sign Joint Development Agreement for Silicon-Enhanced Battery Technology
NEO
globenewswire.comDecember 19, 2024

TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is pleased to announce the joint development agreement (the “Agreement” or “JDA”) with a North American battery cell manufacturer (“JDA Partner”) effective November 30, 2024. This collaboration aims to develop and enhance the performance of silicon anode materials for specialty electric automotive and mobility applications. There are no material terms or considerations as part of this JDA.

NeoGenomics' Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma
NeoGenomics' Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma
NeoGenomics' Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma
NEO
businesswire.comDecember 11, 2024

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics' newly published study shows how ctDNA in MRD may enable earlier identification of disease recurrence for high-risk melanoma patients.

NEO Battery Materials Announces Director Resignation and Updates to Upcoming Corporate Webinar
NEO Battery Materials Announces Director Resignation and Updates to Upcoming Corporate Webinar
NEO Battery Materials Announces Director Resignation and Updates to Upcoming Corporate Webinar
NEO
globenewswire.comDecember 3, 2024

TORONTO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (“NEO” or the “C o mpan y”) (T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, announces that Roberto Fia has resigned from the Company's Board of Directors effective November 29, 2024. NEO would like to thank him for his contributions to date.

FAQ

  • What is the ticker symbol for NeoGenomics?
  • Does NeoGenomics pay dividends?
  • What sector is NeoGenomics in?
  • What industry is NeoGenomics in?
  • What country is NeoGenomics based in?
  • When did NeoGenomics go public?
  • Is NeoGenomics in the S&P 500?
  • Is NeoGenomics in the NASDAQ 100?
  • Is NeoGenomics in the Dow Jones?
  • When was NeoGenomics's last earnings report?
  • When does NeoGenomics report earnings?
  • Should I buy NeoGenomics stock now?

What is the ticker symbol for NeoGenomics?

The ticker symbol for NeoGenomics is NASDAQ:NEO

Does NeoGenomics pay dividends?

No, NeoGenomics does not pay dividends

What sector is NeoGenomics in?

NeoGenomics is in the Healthcare sector

What industry is NeoGenomics in?

NeoGenomics is in the Diagnostics & Research industry

What country is NeoGenomics based in?

NeoGenomics is headquartered in United States

When did NeoGenomics go public?

NeoGenomics's initial public offering (IPO) was on March 16, 2004

Is NeoGenomics in the S&P 500?

No, NeoGenomics is not included in the S&P 500 index

Is NeoGenomics in the NASDAQ 100?

No, NeoGenomics is not included in the NASDAQ 100 index

Is NeoGenomics in the Dow Jones?

No, NeoGenomics is not included in the Dow Jones index

When was NeoGenomics's last earnings report?

NeoGenomics's most recent earnings report was on Nov 5, 2024

When does NeoGenomics report earnings?

The next expected earnings date for NeoGenomics is Feb 18, 2025

Should I buy NeoGenomics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions